TEANECK, N.J., June 17, 2016 -- Holy Name Medical Center is the first hospital in the NY/NJ metropolitan area to use digital monitoring technology to continuously track patients' vital signs. The ViSi® Mobile device, about the size of a business card, is worn on the wrist and transmits patient information to clinicians on an ongoing basis. It is the first body-worn monitor able to non-invasively measure all core vital signs including blood pressure, heart or pulse rate, electrocardiogram or heart rhythm, blood oxygenation, respiration rate and skin temperature. The system will enhance patient safety by enabling early detection of patient deterioration and help ensure a successful response to rescue situations.
"We are always looking for ways to improve the patient experience," said Sheryl Slonim, DNP, RN-BC, NEA-BC, APN-C, Executive Vice President, Patient Care Services and Chief Nursing Officer. "The monitoring system runs on the hospital's wireless network, and any abnormal changes in patients' vital signs are sent to their primary nurses so they can receive immediate attention which will help prevent adverse outcomes."
Typically, nurses check patient vital signs during routine rounds that occur every 6-8 hours. The intermittent checks can disturb patients, while only providing snapshots of vital sign data rather than continuous information. With the ViSi system, if a patient's vital signs move beyond selected ranges the system's alarm system will warn clinicians, so the appropriate intervention can be taken.
In addition to supporting safety, the system also aligns with Holy Name's ongoing efforts to improve the overall healing experience. The lightweight device promotes mobility – patients are able to get out of bed, walk around, shower and undergo physical therapy – all while remaining connected to clinicians.
"The number one benefit is improved patient safety," says Michael Maron, President and CEO. "While real-time patient monitoring is a trend that is just beginning to take hold in leading medical institutions throughout the nation, Holy Name has been testing this technology for years in conjunction with the Telemedicine and Advanced Technology Research Center of the US Department of Defense. Integrating the ViSi Mobile Technology System into our patient care model supports the hospital's long-standing commitment to delivering the highest standard of patient care and patient safety."
ABOUT HOLY NAME MEDICAL CENTER
Holy Name Medical Center is a fully accredited, not-for-profit healthcare facility based in Teaneck, New Jersey. Founded and sponsored by the Sisters of St. Joseph of Peace in 1925, the comprehensive 361-bed medical center offers leading-edge medical practice and technology administered in an environment rooted in a tradition of compassion and respect for every patient. Holy Name provides high quality health care across a continuum that encompasses education, prevention, early intervention, comprehensive treatment options, rehabilitation and wellness maintenance. To learn more, visit HolyName.org.
CONTACT: Katherine Emmanouilidis
Director, Public Relations & Marketing
Holy Name Medical Center
718 Teaneck Road | Teaneck, NJ 07666
Tel: 201-227-6047
[email protected]


Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Italy Fines Apple €98.6 Million Over App Store Dominance
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 



